IP Verse

Krka competitive analysis

Latest oppositions filed by Krka

Explore patent oppositions filed by Krka against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Oct 9, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4321157
New Use Of A Combination Of An Angiotensin Receptor Blocker (Arb) With A Neutral Endopeptidase Inhibitor (Nepi)NOVARTISJul 23, 2025
EP2818163
Composition For Nasal Application With Improved StabilityMARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGESELLSCHAFTMar 26, 2025
EP3294283
Sacubitril-Valsartan Dosage Regimen For Treating Heart FailureNOVARTISDec 8, 2023
EP3113774
Compositions Of Grapiprant And Methods For Using The SameARATANA THERAPEUTICSSep 21, 2022
EP2922526
Manufacturing Of Semi-Plastic Pharmaceutical Dosage UnitsINTERVETJul 26, 2022
EP2863895
Tablet Formulation Comprising A Peptide And A Delivery AgentNOVO NORDISKJan 14, 2022
EP3173071
Maropitant FormulationLE VETDec 23, 2021
EP2478907
Methods And Compositions For Treating CancerCOUGAR BIOTECHNOLOGYDec 22, 2021
EP3061454
Parasiticidal Oral Veterinary Compositions Comprising Systemically-Acting Active Agents, Methods And Uses ThereofBOEHRINGER INGELHEIM ANIMAL HEALTH USADec 9, 2021
EP2925324
Trans-4-{2-[4-(2,3-Dichlorophenyl)-Piperazin-1-Yl]-Ethyl}-N,N-Dimethylcarbamoyl-Cyclohexylamine For Treating Negative Symptoms Of SchizophreniaRICHTER GEDEON NYRTSep 30, 2021

Latest patents of Krka opposed by its competitors

Explore Krka's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Oct 9, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP2588090
Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable Salts3
EP3309158
Mar 16, 2022Crystalline Form K Of Rivaroxaban And Process For Its Preparation1
EP2459555
Nov 3, 2021Processes For Crystallization Of Rivaroxaban1
EP2585051
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable Salts1

Latest publications and patents of Krka New

Explore the latest publications and patents granted to Krka, showcasing their recent innovations and technological advancements.

Last updated on: Oct 3, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Krka

EP2588090
Nov 22, 2023Pharmaceutical Oral Dosage Forms Comprising Dabigatran Etexilate And Its Pharmaceutically Acceptable SaltsPatent Maintained As Amended
EP3309158
Mar 16, 2022Crystalline Form K Of Rivaroxaban And Process For Its PreparationGranted And Under Opposition
EP2459555
Nov 3, 2021Processes For Crystallization Of RivaroxabanGranted And Under Opposition
EP2585051
Apr 8, 2020Pharmaceutical Oral Dosage Forms Comprising Lercanidipine And Enalapril And Their Pharmaceutically Acceptable SaltsPatent Maintained As Amended

Latest PTAB cases involving Krka

Discover the latest PTAB cases involving Krka, highlighting their recent legal challenges and patent disputes.

Peer Comparison New

IP litigation analysis comparing Krka with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Oct 9, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
KRKA286 - -
BRISTOL MYERS SQUIBB IRELAND - 43 - -
BRISTOL MYERS SQUIBB IRELAND UNLIMITED - 43 - -
NOVARTIS6422 - 21